Dato-DXd approved in US for HR+ breast cancer
20 January 2025 Datroway (datopotamab deruxtecan) approved in the US for patients withpreviously treated metastatic HR-positive, HER2-negative breast cancer First approval in the US for AstraZeneca and Daiichi Sankyo's Datroway based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030 Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone